Head-to-head evidence
Baxdrostat vs VB19055
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
Baxdrostat · Baxfendy
Marketed by AstraZeneca
NCT06034743 · Phase 3 · completed
The trial randomized 794 participants to baxdrostat or matching placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Both prespecified primary blood-pressure endpoints were met at Week 12: the reduction in seated systolic blood pressure was greater with 2 mg and 1 mg baxdrostat than with placebo, with p<0.0001 for each comparison.
Next expected readout: December 2026 · NCT07222917 (registry estimate)
VB19055
Developed by Yangli Pharmaceutical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07833098 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Baxdrostat's landscape · VB19055's landscape